PRECISION PLASMIDS R&D
Dead / Abandoned — Abandoned — no statement of use filed (as of 11 Aug 2025)
What this means for you
This application is over — abandoned 11 Aug 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97619748
- Mark type
- Stylized text
- Filed
- 05 Oct 2022
- Published for opposition
- 09 May 2023
- Abandoned
- 11 Aug 2025
- Attorney of record
- Joshua M. Gerben, Esq.
Goods and services
- Class 040 — Treatment of materials: Manufacturing services for others in the fields of pharmaceutical preparations, biopharmaceutical preparations, biologics, drug products, DNA plasmids, advanced therapeutic medicinal products (ATMPs), principally cell and gene therapies intended for research, clinical and commercial use in humans for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting; production of cell lines for others using lentivirus technology
- Class 042 — Scientific and technological services: Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services in the field of production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and · manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research
Owner
- CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC, KING OF PRUSSIA, PA, US
- CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC, KING OF PRUSSIA, PA, US
Prosecution history
- 11 Aug 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 11 Aug 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Dec 2024 — SOU EXTENSION 3 GRANTED
- 20 Dec 2024 — SOU EXTENSION 3 FILED
- 20 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 28 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Jun 2024 — SOU EXTENSION 2 GRANTED
- 28 Jun 2024 — SOU EXTENSION 2 FILED
- 28 Jun 2024 — SOU TEAS EXTENSION RECEIVED
- 15 Nov 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Nov 2023 — SOU EXTENSION 1 GRANTED
- 13 Nov 2023 — SOU EXTENSION 1 FILED
- 13 Nov 2023 — SOU TEAS EXTENSION RECEIVED
- 04 Jul 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT